Why it matters: The biggest manufacturer of Adderall, Teva Pharmaceuticals, will not be increasing production to address national shortages of ADHD medication. This comes despite a call from the U.S. government for drug makers to increase production. The shortage has been ongoing since fall of 2022 and has led to frustrations for patients and providers.
What they are saying: Teva Pharmaceuticals CEO Richard Francis stated that the company is currently operating at full capacity and blamed previous decreased output on COVID-induced work shortages. The company would need to buy or build more factories to increase production, but it has not commented on whether it plans to do so. The FDA/DEA joint notice urged drug makers to increase production to meet their allotted limits for a controlled substance.
The big picture: The demand for ADHD medication, particularly Adderall, has been growing exponentially. However, the pharmaceutical industry has been unable to keep up with this demand due to manufacturing delays and shortages in materials for synthesis. Patients are reporting issues refilling their prescriptions and facing challenges in accessing their medication.
What to watch: It will be important to monitor whether Teva Pharmaceuticals or other drug manufacturers invest in expanding their infrastructure to increase production. Additionally, the FDA and DEA’s efforts to address the shortage and ensure responsible prescribing practices should be followed.
My take: The shortage of ADHD medication is a concerning issue that affects individuals who rely on these medications for their well-being. While the call for drug makers to increase production is understandable, it is also crucial to address the underlying factors causing the shortage, such as manufacturing delays and shortages in materials. Efforts should be made to improve the availability and accessibility of prescription medications for those who need them.
